According to the 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis, treatment with a tumor necrosis factor inhibitor (TNFi) biologic is recommended over an oral small molecule (OSM) in OSM- and other treatment–naïve patients with active psoriatic arthritis (PsA).
Better luck next time
Read more about the guideline here.
For more psoriatic arthritis content, click here.
Nice job!